BiotechTube
Home/Aprea Therapeutics/Oren Gilad, Ph.D.
OG

Oren Gilad, Ph.D.

President and Chief Executive Officer

Aprea Therapeutics

Therapeutic Areas

Oncology

Aprea Therapeutics Pipeline

DrugIndicationPhase
APR-1051Advanced or Metastatic Solid Tumors (with CCNE1, CCNE2, FBXW7, PPP2R1A, HPV+, or KRAS G12/13 & TP53 mutations)Phase 1
ATRN-119Advanced or Metastatic Solid Tumors (with ATM LOF, ARID1A, or HRD mutations)Phase 1/2a
Undisclosed DDR Target InhibitorAdvanced Solid TumorsPreclinical

Leadership Team at Aprea Therapeutics

JP
John P. Hamill, CPA
Senior Vice President and Chief Financial Officer
View full Aprea Therapeutics profile